Job opportunity: Cereno Scientific is looking for a Director R&D, Clinical Studies & Project Management

Cereno Scientific is developing a unique concept for the prevention of blood clots – the biggest cause of death in the world. The company aims to bring to market a new preventive medicine to treat thrombosis-related disease, offering an opportunity for effective treatment while lowering the risk of serious bleeding complications associated with current treatment with blood-thinning drugs – leading to more effective treatment. Cereno Scientific is located in the BioVentureHub at AstraZeneca Gothenburg.

We are a small, dedicated team now looking for an experienced project manager to deliver our clinical trials program. The successful candidate will have broad experience of managing clinical trials, especially in early-stage drug development.

You should have an entrepreneurial mindset and be excited at the prospect of working in a small, growth-oriented biotech company, which can sometimes be equally challenging as it is exhilarating. You will have a broad responsibility, ranging from being the primary contact with CROs and regulatory agencies, through study protocol design and initiation, to final reports of our clinical studies. In addition, you will be in charge of and drive project management of non-clinical projects in R&D. 

You are a positive, highly motivated person who likes to work independently. You should be an excellent problem solver and networker. Speed and quality of delivery are important success factors in this role. We’d love to hear from you if you’re interested.

Please contact our CEO, Sten R. Sörensen on +46 73 374 03 74 or sten.sorensen@cerenoscientific.com if you have any questions.

• Application deadline: 16 June 2017
• Send your application to: sten.sorensen@cerenoscientific.com
• Start: ASAP
• Location: BioVentureHub at AstraZeneca Gothenburg
• Learn more about us: www.cerenoscientific.com

About Cereno Scientific AB 

Cereno Scientific develops preventive medicines to treat thrombosis-related disease, such as myocardial infarction and stroke. These novel therapeutics stimulate the body's own intelligent clot-busting system, and are being developed to treat thrombosis-related cardiovascular diseases on the global market. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn leads to a high risk of new blood clots. The benefit with Cereno Scientific's drug candidate, CS1, is an improved balance between preventing blood clots and treatment-related side effects - leading to more effective treatment. CS1 is a re-formulation of a known compound and, as such, is expected to have a relatively short development time. It is based on many years of research and its effectiveness on risk factors is documented in experimental studies and early clinical studies. Preventive effectiveness against blood clots has been demonstrated in animal in vivo studies. Indication of clinical preventive effectiveness against heart attacks has been demonstrated in two large epidemiological studies. CS1 has a unique mechanism of action, a potentially wide range of indication opportunities connected to large blood clot-related diseases and, consequently, a large market potential. The Göteborg-based company is listed on the AktieTorget stock market, conducts research activities at AstraZeneca's BioVentureHub in Göteborg and is supported by GU Ventures. For more information, see www.cerenoscientific.se.